Stay updated with breaking news from Head Specialty. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Completed enrollment in pivotal Phase 3 “DRAGON” trial for Tinlarebant in adolescent Stargardt disease with 104 subjects enrolled across 11 countries worldwideFirst subject dosed with Tinlarebant...
Completed enrollment in pivotal Phase 3 “DRAGON” trial for Tinlarebant in adolescent Stargardt disease (“STGD1”) with 104 subjects enrolled across 11...
LBS-008 (aka Tinlarebant) was safe and well tolerated in adolescent Stargardt Disease (STGD1) subjects at 12-month time pointThe majority of the subje
LBS-008 (aka Tinlarebant) was safe and well tolerated in adolescent Stargardt Disease (STGD1) subjects at 12-month time pointThe majority of the subjects...
02.10.2022 - LBS-008 (aka Tinlarebant) was safe and well tolerated in adolescent Stargardt Disease (STGD1) subjects at 12-month time pointThe majority of the subjects showed stabilization of BCVA in at least one eyeA trend for preventing or slowing expansion of ... Seite 1